Market Trends of Vulvodynia Treatment Industry
This section covers the major market trends shaping the Vulvodynia Treatment Market according to our research experts:
Local Anesthetics Segment Expected to Hold a Significant Share in the Vulvodynia Treatment Market
Local anesthetics are expected to hold a significant share of the vulvodynia treatment market. Local anesthetics restrict the transmission of nerve impulses from the targeted region to the spinal cord. In addition, local anesthetics are much safer to use and have fewer side effects than general anesthetics. The major factors contributing to the segment's growth are the growing demand for local anesthetics as well as the implementation of strategic initiatives undertaken by the market players. For instance, as per an April 2022 published article by the National Library of Medicine, therapy with local anesthetics (TLA) successfully reduced vulvodynia in 36 of 45 patients (80% of responders), and the numeric analog scale (NAS) reduction was from 7.9 to 2.4.
Furthermore, according to an article published by Sexual Medicine, in April 2022, a symptom-oriented form of therapy with local anesthetics provides a highly effective and easy-to-apply approach to treating vulvodynia, especially if integrating the novel perineal pudendal injection technique. Thus, the advantage of local anesthesia to treat vulvodynia is expected to drive the growth of the segment.
Thus, owing to the above-mentioned factors, the segment is expected to witness significant growth over the forecast period.
North America Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period
North America is anticipated to account for a significant share of the vulvodynia treatment market during the forecast period. This is attributed to the increasing incidence of females developing vulvodynia, the presence of key market players, substantial R&D, and healthcare spending. Moreover, rising vulvodynia awareness, a surge in novel treatment choices, and vulvodynia's expanding economic and social impact is expected to boost the growth of the market within North America. Within North America, the United States has held a major share of the market. The major factors contributing to the market's growth are the increasing burden of vulvodynia and the increasing demand for vulvodynia treatment. For instance, according to a National Vulvodynia Association article, Harvard research supported by the National Institutes of Health (NIH) found that in 2022, 60% of affected women saw three or more doctors before being diagnosed with vulvodynia. Thus, this indicates the rising demand for vulvodynia treatment in the United States, thereby contributing to market growth.
Moreover, in December 2022, SCYNEXIS Inc. announced that the US Food and Drug Administration (FDA) approved a second indication for BREXAFEMME (ibrexafungerp tablets) for the reduction in the incidence of recurrent vulvovaginal candidiasis (RVVC).
Thus, due to the above-mentioned factors, the market is estimated to witness significant growth over the forecast period.
